Table 2.
PPAR Agonists in Ongoing Clinical Trials against NAFLD/NASH (as of 2023/8/14).
| Drug | NCT Number | Phase | Status | Participants | Subject | Start Date | ESC Date |
|---|---|---|---|---|---|---|---|
| PPARα/δ/γ pan agonists | |||||||
| Chiglitazar |
NCT05193916 (https://classic.clinicaltrials.gov/ct2/show/NCT05193916) |
2 | Recruiting | 100 | NASH with elevated triglyceride and insulin resistance | 2022/3/21 | (2023/11) |
| Lanifibranor |
NCT03459079 (https://classic.clinicaltrials.gov/ct2/show/NCT03459079) |
2 | Recruiting | 54 | T2DM and NAFLD | 2018/8/14 | (2024/4/14) |
|
NCT04849728 (https://classic.clinicaltrials.gov/ct2/show/NCT04849728) |
3 | Recruiting | 1000 | NASH with F2/F3 stage of liver fibrosis | 2021/8/19 | (2026/9/30) | |
|
NCT05232071 (https://classic.clinicaltrials.gov/ct2/show/NCT05232071) |
2 | Recruiting | 63 | T2DM and NASH | 2022/6/29 | (2023/12/31) | |
| PPARα/γ dual agonist | |||||||
| Saroglitazar |
NCT03617263 (https://classic.clinicaltrials.gov/ct2/show/NCT03617263) |
2 | Recruiting | 90 | NAFLD in women with polycystic ovarian syndrome | 2018/12/4 | (2024/7) |
|
NCT03639623 (https://classic.clinicaltrials.gov/ct2/show/NCT03639623) |
2 | Recruiting | 15 | Liver transplant recipients with NAFLD | 2019/2/25 | 2023/6 | |
|
NCT04469920 (https://classic.clinicaltrials.gov/ct2/show/NCT04469920) |
1 | Recruiting | 100 | NASH with advanced fibrosis | 2020/7/16 | (2024/10) | |
|
NCT05011305 (https://classic.clinicaltrials.gov/ct2/show/NCT05011305) |
2 | Recruiting | 240 | NASH | 2021/8/18 | (2023/12) | |
|
NCT05211284 (https://classic.clinicaltrials.gov/ct2/show/NCT05211284) |
2 | Recruiting | 160 | NASH with human immunodeficiency virus | 2022/9/26 | (2025/3/1) | |
|
NCT05872269 (https://classic.clinicaltrials.gov/ct2/show/NCT05872269) |
4 | Not yet | 1500 | NAFLD with comorbidities (obesity, T2DM, dyslipidemia, or metabolic syndrome) | 2023/7/20 | (2025/6/10) | |
| PPARγ agonist | |||||||
| Pioglitazone |
NCT04501406 (https://classic.clinicaltrials.gov/ct2/show/NCT04501406) |
2 | Recruiting | 166 | NASH in T2DM | 2020/12/15 | (2027/8/31) |
|
NCT04976283 (https://classic.clinicaltrials.gov/ct2/show/NCT04976283) |
4 | Recruiting | 123 | Liver fat in T2DM and NAFLD | 2021/9/15 | (2023/11/15) | |
|
NCT05254626 (https://classic.clinicaltrials.gov/ct2/show/NCT05254626) |
4 | Recruiting | 100 | NASH | 2022/8/1 | (2025/8) | |
|
NCT05305287 (https://classic.clinicaltrials.gov/ct2/show/NCT05305287) |
4 | Recruiting | 60 | NAFLD in T2DM | 2022/11/1 | (2027/3/31) | |
|
NCT05422092 (https://classic.clinicaltrials.gov/ct2/show/NCT05422092) |
NA | Not yet | 80 | NAFLD in T2DM | 2022/9/20 | (2023/12) | |
|
NCT05513729 (https://classic.clinicaltrials.gov/ct2/show/NCT05513729) |
NA | Recruiting | 80 | NAFLD in T2DM | 2022/8/18 | (2024/3/1) | |
|
NCT05605158 (https://classic.clinicaltrials.gov/ct2/show/NCT05605158) |
3 | Not yet | 56 | NASH | 2022/11 | (2024/11) | |
|
NCT05813249 (https://classic.clinicaltrials.gov/ct2/show/NCT05813249) |
4 | Recruiting | 180 | NAFLD in obesity and/or T2DM | 2023/2/15 | (2024/8/15) | |
|
NCT05942963 (https://classic.clinicaltrials.gov/ct2/show/NCT05942963) |
4 | Not yet | 240 | NAFLD and T2DM | (2023/10) | (2024/4) | |
NCT, US National Library of Medicine Clinical Trials; NA, not applicable; ESC, estimated study completion date with future date in parentheses.